Skip to main content

Table 6 Subgroup analysis for the effect of statin therapy on cardiovascular death

From: Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Subgroup Value Reference Statin Control Relative risk (95% CI) p value Heterogeneity p value for heterogeneity
    (Event/total) (Event/total)     
Mean Age > = 65 24,25 76/1425 99/1479 0.79 [0.59, 1.06] 0.114 0% 0.81
  <65 29, 31, 32,34 4/480 5/477 0.83 [0.24, 2.96] 0.778 0% 0.53
Cardiovascular History Yes 29,31,34 76/1280 98/1230 0.80 [0.60, 1.07] 0.126 0% 0.69
  No 25,32 0/192 2/205 0.35 [0.04, 3.28] 0.354 0% 0.96
Baseline Creatinine > = 1.5 25,29 17/333 28/339 0.63 [0.35, 1.12] 0.116 0% 0.68
  <1.5 24, 31,32,34 63/1572 76/1617 0.85 [0.62, 1.18] 0.338 0% 0.94
LDL Cholesterol Lowering > = 30% 29 17/286 27/293 0.65 [0.36, 1.16] 0.142 - -
  <30% 24,25,32 4/625 6/636 0.75 [0.23, 2.42] 0.625 0% 0.73
Follow-up time > = 3 24, 29,31,32,34 80/1858 103/1910 0.80 [0.60, 1.06] 0.122 0% 0.90
  <3 25 0/47 1/46 0.33 [0.01, 7.81] 0.489 - -
  1. Abbreviations: CI confidential interval, LDL low density lipoprotein.